other material
confidence high
sentiment neutral
materiality 0.60
Forte Biosciences advances FB102 into celiac trial; Q3 net loss $8.4M
Forte Biosciences, Inc.
- Dosing begun in celiac disease trial; topline data expected Q2 2025.
- Phase 1 healthy-volunteer study of FB102 completed with good safety and NK cell reduction.
- Q3 R&D expense $5.9M vs $6.4M YoY; net loss per share $(4.54) vs $(6.57).
- Cash and equivalents $16.4M as of Sept 30, 2024; shares outstanding 1.46M after 1:25 reverse split.